Looking to sell Seaport Therapeutics stock or options?
Seaport Therapeutics is focused on creating innovative neuropsychiatric medications to address unmet patient needs. The company's drugs are designed for oral bioavailability, which avoids first-pass metabolism and minimizes liver toxicity and other adverse effects. This approach helps patients manage neuropsychiatric disorders more effectively.
CPP Investments, Gray's Creek Capital Partners, Foresite Capital, Hawktail, T. Rowe Price Group, Third Rock Ventures, Sofinnova Investments, The Invus Group, Goldman Sachs Asset Management, PureTech Health, ARCH Venture Partners, Monash University Endowment, General Atlantic, Monash University.